Key result
Non-diabetic hemodialysis patients had higher platelet aggregation threshold index values compared to healthy controls.
Why the study?
Can the screen filtration pressure (SFP) method effectively measure whole-blood platelet aggregation and the effect of antiplatelet agents in hemodialysis patients?
Cross-Sectional (n=62)
Can the screen filtration pressure (SFP) method effectively measure whole-blood platelet aggregation and the effect of antiplatelet agents in hemodialysis patients?
Whole-blood analysis by the screen filtration pressure method is a promising tool for monitoring platelet function and the effects of antiplatelet therapy in hemodialysis patients.
Answers are grounded in this paper and cite their sources.
Supports SFP method for platelet monitoring in hemodialysis; hypothesis-generating before guiding antiplatelet therapy.
A semi-automatic, whole-blood aggregometer based on the screen filtration pressure (SFP) method is now widely used clinically and in research, but has not been used with hemodialysis (HD) patients. We measured whole-blood platelet aggregation in HD patients by the SFP method. This retrospective cross-sectional study included 62 HD patients, of whom 47 were non-diabetic and 15 were diabetic; we also included a control group of healthy, non-uremic subjects. With the t-test, we examined differences in the platelet aggregation threshold index (PATI) in meaningful sub-groupings of the HD patients, depending on whether or not they had diabetes, and whether or not they had been given antiplatelet agents. Considering the non-diabetic HD patients first, their PATI values were significantly higher than those values in the control subjects (3.1 [1.0-5.2] vs. 1.8 [1.3-2.3] µM, P<0.001). The non-diabetic HD patients taking antiplatelet agents showed significantly (1.9 times) higher PATI values than the non-diabetic HD patients without antiplatelet agents (4.4 [1.8-7.0] vs. 2.3 [1.3-3.3] µM, P=0.003). We observed similar trends among diabetic HD patients. Whole-blood analysis by the SPF method seems to be a promising way of monitoring platelet function for HD patients.
No takes yet. Share an insight, caveat, or question.
Waki et al. (2010) conducted a cross-sectional in Hemodialysis (n=62). Hemodialysis vs. Healthy, non-uremic subjects was evaluated on Platelet aggregation threshold index (PATI) (p=<0.001). Non-diabetic hemodialysis patients had higher platelet aggregation threshold index values compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: